Skip to main content
SpringerLink
Log in

Effect of Lipid Lowering Medications on PON1

  • Chapter
The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism

Part of the book series: Proteins And Cell Regulation ((PROR,volume 6))

Abstract

Lipid abnormalities are among the most important risk factors of the development of atherosclerosis. Inhibitors of 3-hydroxy-methyglutaryl-coenzyme A reductase (statins) and peroxisome proliferator-activated receptor (PPAR) alpha ligand (fibrates) are widely used as lipid lowering drugs in patients with disturbed lipid metabolism. Apart from reducing plasma lipid levels, these agents have additional beneficial effects on other processes involved in the atherosclerotic process. In the last few years the favourable effect of these drugs on human paraoxonase-1 activity was extensively investigated both in in vitro and in vivo studies. This chapter summarizes the results of in vivo and in vitro studies, and the putative mechanisms of altered PON1 activity caused by statin and fibrate administration. The possible causes of discrepancies in currently available data will be also discussed

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Argmann CA, Edwards JY, Sawyez CG, O’Neil CH, Hegele RA, Pickering JG, Huff MW. 2005, Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J. Biol. Chem. 280:22212–22221

    Article  CAS  PubMed  Google Scholar 

  • Audikovszky M, Pados G, Seres I, Harangi M, Fulop P, Katona E, Illyes L, Winkler G, Katona EM, Paragh G. 2006, Orlistat increases serum paraoxonase activity in obese patients. Nutr. Metab. Cardiovasc Dis. [Epub ahead of print]

    Google Scholar 

  • Aviram M, Rosenblat M. 2005, Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr. Opin. Lipidol. 16:393–399

    Article  CAS  PubMed  Google Scholar 

  • Aviram M, Rosenblat M, Bisgaier CL, Newton RS. 1998, Atorvastatin and gemfibrozil metabolites, but not parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138:271–80

    Article  CAS  PubMed  Google Scholar 

  • Ballantyne C, Arroll B, Shepherd J. 2005, Lipids and CVD management: towards a global consensus. Eur. Heart. J. 26(21):2224–31

    Article  PubMed  Google Scholar 

  • Balogh Z, Fülöp P, Seres I, Harangi M, Katona E, Kosztáczky B, Paragh GY. 2001a, Effects of simvastatin on serum paraoxonase activity. Clin. Drug. Invest. 21:505–10

    Article  CAS  Google Scholar 

  • Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G. 2001b, Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of beneficial action of fibrates? Diab. Met. 27:604–10

    CAS  Google Scholar 

  • Beltowski J, Wojcicka G, Jamroz A. 2002a, Differential effect of 3-hydroxy-3-methylglutaryl coemzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Pol. J. Pharmacol. 54:661–71

    CAS  Google Scholar 

  • Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A. 2002b, The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity. J. Physiol. Pharmacol. 53:463–75

    CAS  Google Scholar 

  • Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N. 2005, Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocrinol. Metab. 90(12):6454–9

    Article  CAS  PubMed  Google Scholar 

  • Davidson M.H. 2005, Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 111(18):2280–1

    Article  PubMed  Google Scholar 

  • Deakin S, Leviev I, Guernier S, James RW. 2003, Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol reulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23:2083–89

    Article  CAS  PubMed  Google Scholar 

  • Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. 2005, Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid. Res. 46(6):1239–47

    Article  CAS  PubMed  Google Scholar 

  • Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN. 1998, Effects of two different fibric acid derivates on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type Iib hyperlipoproteinaemia. Atherosclerosis 138:217–25

    Article  CAS  PubMed  Google Scholar 

  • Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. 2002, Atorvastatin therapy in hypercholesterolemic patients suppressed cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 64:179–85

    Article  Google Scholar 

  • Giroux LM, Davignon J, Naruszewicz M. 1993, Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta. 1165(3):335–8

    CAS  PubMed  Google Scholar 

  • Gouédard C, Koum-Besson N, Barouki R, Morel Y. 2003, Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 64(4):945–56

    Article  Google Scholar 

  • Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. 2004, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44:720–732

    Article  PubMed  Google Scholar 

  • Harangi M, Seres I, Varga Z, Emri G, Szilvassy Z, Paragh G, Remenyik E. 2004, Atorvastatin effect on HDL associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharm. 60:685–91

    Article  CAS  Google Scholar 

  • Heinecke JW. 2006, Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander? J. Exp. Med. 203(4):813–6

    Article  CAS  PubMed  Google Scholar 

  • Himbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M. 2005, The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J. Intern. Med. 258(5):442–9

    Article  CAS  PubMed  Google Scholar 

  • Israelian-Konaraki Z, Reaven PD. 2005, Peroxisome proliferator-activated receptor-alpha and atherosclerosis:from basic mechanisms to clinical implications. Cardiology 103:1–9

    Article  PubMed  Google Scholar 

  • Kassai A, Illyes L, Mirdamadi HZ, Seres I, Kalmar T, Audikovszky M, Paragh G. 2006, The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin. Biochem. [Epub ahead of print]

    Google Scholar 

  • Khersonsky O, Tawfik DS. 2006, The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 281(11):7649–56

    Article  CAS  PubMed  Google Scholar 

  • Kleemann M, Kooistra T. 2005, HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5:441–453

    Article  CAS  PubMed  Google Scholar 

  • Krauss RM, Siri PW. 2004, Dyslipidemia in type 2 diabetes. Med Clin North Am. 88: 897–909

    Article  CAS  PubMed  Google Scholar 

  • Kural BV, Orem C, Uydu HA, Alver A, Orem A. 2004, The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the antioxidant system in patients with dyslipidemia. Coron. Artery. Dis. 15:277–83

    Article  PubMed  Google Scholar 

  • Li AC, Glass CK. 2004, PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid. Res. 45(12):2161–73

    Article  CAS  PubMed  Google Scholar 

  • Marx N, Duez H, Fruchart JC, Staels B. 2004, Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94(9):1168–78

    Article  CAS  PubMed  Google Scholar 

  • Morrow JD. 2005, Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25(2):279–86

    Article  CAS  PubMed  Google Scholar 

  • Nguyen SD, Sok D. 2003, Benefitial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilisation. Biochem. J. 375:257–85

    Article  Google Scholar 

  • Ota K, Suehiro T, Arii K, Ikeda Y, Kumon Y, Osaki F, Hashimoto K. 2005, Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 54:142–50

    Article  CAS  PubMed  Google Scholar 

  • Paragh G, Balogh Z, Seres I, Harangi M, Boda J, Kovacs P. 2000, Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin. Drug. Invest. 19:277–82

    Article  CAS  Google Scholar 

  • Paragh G, Seres I, Balogh Z, Harangi M, Illyés L, Boda J, Varga ZS, Kovács P. 2003, The effect of micronised fenofibrate on serum paraoxonase activity in patients with coronary heart disease. Diab. Met. 29:613–18

    Article  CAS  Google Scholar 

  • Paragh G, Töröcsik D, Seres I, Harangi M. 2004, Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr. Med. Res. Opin. 20:1321–27

    Article  CAS  PubMed  Google Scholar 

  • Saini HK, Xu YJ, Arneja AS, Tappia PS, Dhalla NS. 2005,Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell. Mol. Med. 9:818–839

    Article  CAS  PubMed  Google Scholar 

  • Soccio RE, Breslow JL. 2004, Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 24(7):1150–60

    Article  CAS  PubMed  Google Scholar 

  • Tomás M, Sentí M, García-Faria F, Vila J, Rorrents A, Covas M, Marrugat J. 2000, Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patiens. Arterioscler. Thromb. Vasc. Biol. 20:2113–19

    PubMed  Google Scholar 

  • Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD. 2003, Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid. Res. 44:927–34

    Article  CAS  PubMed  Google Scholar 

  • Tsimihodimos V, Karabina SAP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. 2002, Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIa and type IIb. Arterioscler. Throm. Vasc. Biol. 22:306–11

    Article  CAS  Google Scholar 

  • Turay J, Grnaková V, Valka J. 2000, Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familial hyperlipoproteinaemia treated with ciprofibrate. Drug. Exp. Clin. Res. 26:83–88

    CAS  Google Scholar 

  • van Wijk J, Coll B, Cabezas MC, Koning E, Camps J, Mackness B, Joven J. 2006, Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol. 33:1134–1137

    Article  PubMed  Google Scholar 

  • Weber LW, Boll M, Stampfl A. 2004, Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World. J. Gastroenterol. 10:3081–7

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Medicine, Medical and Health Science Center, University of Debrecen, Hungary

    G. Paragh, M. Harangi & I. Seres

Authors
  1. G. Paragh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Harangi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Seres
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Manchester, U.K

    Bharti Mackness

  2. University of Manchester, U.K

    Mike Mackness

  3. Technion Faculty of Medicine, Haifa, Israel

    Michael Aviram

  4. University of Debrecen, Hungary

    György Paragh

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Paragh, G., Harangi, M., Seres, I. (2008). Effect of Lipid Lowering Medications on PON1. In: Mackness, B., Mackness, M., Aviram, M., Paragh, G. (eds) The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Proteins And Cell Regulation, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6561-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-6561-3_17

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-6560-6

  • Online ISBN: 978-1-4020-6561-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation